Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Honest And Straightforward” 483 Responses May Avert Warning Letters

Executive Summary

CDER is weighing companies' responses to FDA-483 inspection reports in considering whether to issue warning letters, Center for Drug Evaluation & Research Office of Compliance Director David Horowitz said

You may also be interested in...

FDA GMP Dispute Resolution Guidance Allows 10 Days To Raise Objections

FDA's dispute resolution draft guidance will allow manufacturers 10 days to challenge FDA inspection findings

GMP Quality Management Systems For FDA Will Be Proposed By December

FDA expects to release a draft on improving the agency's good manufacturing practices management systems by Dec. 1

GMP Dispute Resolution Draft Guidance To Issue In Next Few Months

FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts